###begin article-title 0
Doxycycline Reduces Plasma VEGF-C/sVEGFR-3 and Improves Pathology in Lymphatic Filariasis
###end article-title 0
###begin p 1
###xml 843 852 842 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 1250 1259 1249 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 2320 2332 2319 2331 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">W. bancrofti</named-content>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
###xml 747 755 <span type="species:ncbi:9606">patients</span>
###xml 815 823 <span type="species:ncbi:9606">Patients</span>
###xml 1140 1148 <span type="species:ncbi:9606">patients</span>
###xml 1361 1369 <span type="species:ncbi:9606">patients</span>
###xml 1516 1524 <span type="species:ncbi:9606">patients</span>
###xml 1755 1763 <span type="species:ncbi:9606">patients</span>
###xml 1873 1881 <span type="species:ncbi:9606">patients</span>
###xml 1919 1927 <span type="species:ncbi:9606">patients</span>
###xml 2035 2043 <span type="species:ncbi:9606">patients</span>
###xml 2090 2098 <span type="species:ncbi:9606">patients</span>
###xml 2320 2332 <span type="species:ncbi:6293">W. bancrofti</span>
###xml 2578 2586 <span type="species:ncbi:9606">patients</span>
Lymphatic filariasis is a disease of considerable socioeconomic burden in the tropics. Presently used antifilarial drugs are able to strongly reduce transmission and will thus ultimately lower the burden of morbidity associated with the infection, however, a chemotherapeutic principle that directly induces a halt or improvement in the progression of the morbidity in already infected individuals would constitute a major lead. In search of such a more-effective drug to complement the existing ones, in an area endemic for bancroftian filariasis in Ghana, 33 microfilaremic and 18 lymphedema patients took part in a double-blind, placebo-controlled trial of a 6-wk regimen of 200 mg/day doxycycline. Four months after doxycycline treatment, all patients received 150-200 mug/kg ivermectin and 400 mg albendazole. Patients were monitored for Wolbachia and microfilaria loads, antigenemia, filarial dance sign (FDS), dilation of supratesticular lymphatic vessels, and plasma levels of lymphangiogenic factors (vascular endothelial growth factor-C [VEGF-C] and soluble vascular endothelial growth factor receptor-3 [(s)VEGFR-3]). Lymphedema patients were additionally monitored for stage (grade) of lymphedema and the circumferences of affected legs. Wolbachia load, microfilaremia, antigenemia, and frequency of FDS were significantly reduced in microfilaremic patients up to 24 mo in the doxycycline group compared to the placebo group. The mean dilation of supratesticular lymphatic vessels in doxycycline-treated patients was reduced significantly at 24 mo, whereas there was no improvement in the placebo group. Preceding clinical improvement, at 12 mo, the mean plasma levels of VEGF-C and sVEGFR-3 decreased significantly in the doxycycline-treated patients to a level close to that of endemic normal values, whereas there was no significant reduction in the placebo patients. The extent of disease in lymphedema patients significantly improved following doxycycline, with the mean stage of lymphedema in the doxycycline-treated patients being significantly lower compared to placebo patients 12 mo after treatment. The reduction in the stages manifested as better skin texture, a reduction of deep folds, and fewer deep skin folds. In conclusion, a 6-wk regimen of antifilarial treatment with doxycycline against W. bancrofti showed a strong macrofilaricidal activity and reduction in plasma levels of VEGF-C/sVEGFR-3, the latter being associated with amelioration of supratesticular dilated lymphatic vessels and with an improvement of pathology in lymphatic filariasis patients.
###end p 1
###begin title 2
Synopsis
###end title 2
###begin p 3
###xml 196 202 <span type="species:ncbi:9606">people</span>
Lymphatic filariasis, caused by filarial worms, is transmitted by mosquitoes. The infection leads to pathology such as edema of the legs (lymphedema) or the scrotum (hydrocele). About 120 million people are estimated to be infected, and 1.2 billion are at risk of infection. The currently used drugs (diethylcarbamazine [DEC] or ivermectin plus albendazole) to treat the disease are able to kill most of the larval stage (microfilariae) in the blood but have either no (ivermectin) or partial (DEC) effect on the adult worms that cause the pathology. They also do not sufficiently halt the progression of pathology, such as, lymph vessel dilation, hydrocele, and lymphedema.
###end p 3
###begin p 4
###xml 210 216 <span type="species:ncbi:9606">people</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
###xml 764 769 <span type="species:ncbi:9606">human</span>
###xml 925 932 <span type="species:ncbi:9606">persons</span>
In search of a more effective drug capable of killing the adult worms, and also of halting the progression of the disease in already infected individuals, the authors recruited, in an endemic area in Ghana, 33 people who were infected with the worm and microfilaremic but had not yet developed the disease, as well as 18 lymphedema patients, and treated them with either 200 mg/d doxycycline or matching placebo for 6 wk. The findings presented here reveal that doxycycline is able to kill the adult worms, improves lymphatic vessel dilation, and ameliorates the conditions of lymphedema patients significantly. This suggests that doxycycline can be used to treat lymphatic filarial infections and pathology, making doxycycline the first drug already approved for human use and considered for use as an adjunct to current control programs, which in addition to parasite control achieves improvement of the quality of life of persons with pathology.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b001">1</xref>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b002">2</xref>
###xml 70 76 <span type="species:ncbi:9606">humans</span>
###xml 602 608 <span type="species:ncbi:9606">humans</span>
Bancroftian filariasis is a mosquito-transmitted parasitic disease of humans characterized by lymphangitis, hydrocele, lymphedema, and elephantiasis, and is one of the most common causes of global disability [1]. The disease has been considered to be potentially eradicable due to the fact that antifilarial drugs currently used could break the cycle of transmission in endemic areas. The goals of the current global lymphatic filariasis (LF) elimination program are (1) to reduce microfilaremia levels with filaricidal drugs to a level that is too low to sustain transmission of filarial parasites to humans; and (2) to reduce the morbidity associated with chronic filarial disease [2].
###end p 6
###begin p 7
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b003">3</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b004">4</xref>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b005">5</xref>
###xml 512 513 512 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b006">6</xref>
###xml 733 734 733 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b007">7</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b012">12</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b013">13</xref>
The antifilarial drugs currently used, diethylcarbamazine (DEC) and ivermectin, are predominantly active against microfilariae (MF), with DEC showing partial activity against adult worms [3]. Mass drug applications using DEC, which acts on the adult worms that are believed to be major inducers of the lymphatic pathology, have been reported to lead to an improvement of pre-existing lymphedema and hydrocele [4,5]; similar findings were observed in a controlled treatment study using different regimens of DEC [6]. However, these results are not unequivocal, since several other studies could not confirm these findings even when DEC was administered for 12 d instead of the usual single dose of the mass drug administration (MDA) [7-12]. This inconsistency was also acknowledged in a conference by experts of the "Filariasis Community of Scientists in Association with an LF Research Forum" convened in Philadelphia, December 2003 [13].
###end p 7
###begin p 8
###xml 393 402 393 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 445 457 445 457 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">W. bancrofti</named-content>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b014">14</xref>
###xml 492 501 492 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b014">14</xref>
###xml 671 680 671 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 773 782 773 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b015">15</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b017">17</xref>
###xml 445 457 <span type="species:ncbi:6293">W. bancrofti</span>
###xml 822 826 <span type="species:ncbi:10090">mice</span>
Thus, a drug with stronger macrofilaricidal activity than reported for DEC, which simultaneously has ameliorating effects on lymphatic vessels, could considerably improve the prospect of developing a treatment for lymphatic pathology. One aspect of the biology of filarial nematodes that could be exploited in the effort to advance the elimination program is the presence of the endosymbiotic Wolbachia found in most filarial species, including W. bancrofti [14]. Recent studies of symbiotic Wolbachia organisms suggest that these bacteria are important both as chemotherapeutic targets and disease-causing organisms [14]. In a laboratory model of onchocercal keratitis, Wolbachia was shown to mediate neutrophil infiltration and stromal haze when a worm extract including Wolbachia antigens was injected into the eyes of mice [15-17].
###end p 8
###begin p 9
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b018">18</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b021">21</xref>
###xml 125 130 <span type="species:ncbi:9606">human</span>
The events that lead to the development of chronic pathology in LF are not fully understood, but the immune responses of the human host to the parasites are believed to play a significant role in determining the pathological manifestations of disease in infected individuals [18-21].
###end p 9
###begin p 10
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b022">22</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b023">23</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b024">24</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b026">26</xref>
The lymphatic vascular system is important for immune surveillance, tissue fluid homeostasis, and fat absorption [22,23]. Perturbations in the maintenance and function of the lymphatic system can lead to a variety of pathological disorders, including lymphatic dilation and lymphedema [24-26].
###end p 10
###begin p 11
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b027">27</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b028">28</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b029">29</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b032">32</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b033">33</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b034">34</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b032">32</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b035">35</xref>
###xml 808 818 808 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">keratin 14</italic>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b036">36</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b036">36</xref>
###xml 1465 1467 1465 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b037">37</xref>
###xml 193 199 <span type="species:ncbi:9606">humans</span>
###xml 399 414 <span type="species:ncbi:10090">transgenic mice</span>
###xml 720 735 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1110 1125 <span type="species:ncbi:10090">transgenic mice</span>
Recent studies on the molecular mechanisms controlling the lymphatic vessels have shown that vascular endothelial growth factors C (VEGF-C) and VEGF-D specifically control lymphangiogenesis in humans [27,28] by activating the VEGF receptor-3 (VEGFR-3) [29-32], which is principally restricted to the lymphatic endothelium in adults [33,34]. In animal models, overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic endothelial proliferation and dilation of lymph vessels [32] with a resemblance to lymphatics infected with filarial parasites [35]. Additional evidence for the role of VEGF-C/VEGF-D/VEGFR-3 in the pathogenesis of lymphatic dilation and lymphedema stems from experimental studies in transgenic mice with skin specific overexpression of soluble VEGFR-3 (sVEGFR-3) using a keratin 14 transgenic promoter [36]. In this genetic model, sVEGFR-3 is secreted at high levels by basal epidermal keratinocytes and binds the lymphangiogenesis factors VEGF-C and VEGF-D, thereby preventing them from activating membrane-bound VEGFR-3 on lymphatic endothelium [36]. These K14/ sVEGFR-3 transgenic mice lack a functional cutaneous lymphatic system and are characterized by lymphedema formation in the skin. The expression of VEGF-C has been shown to be up-regulated by proinflammatory cytokines like interleukin (IL)-1B and tumor necrosis factor (TNF), suggesting that proinflammatory cytokines could affect the lymphatic vessels via VEGF-C [37].
###end p 11
###begin p 12
###xml 41 50 41 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 74 80 74 80 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Brugia</named-content>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b038">38</xref>
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Brugia</italic>
###xml 182 201 182 201 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Onchocerca volvulus</named-content>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b039">39</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b040">40</xref>
###xml 480 505 480 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acanthocheilonema viteae,</italic>
###xml 545 555 545 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia,</italic>
###xml 579 590 579 590 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">O. volvulus</named-content>
###xml 664 673 664 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b041">41</xref>
###xml 782 791 782 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 943 952 943 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 182 201 <span type="species:ncbi:6282">Onchocerca volvulus</span>
###xml 261 266 <span type="species:ncbi:9606">human</span>
###xml 480 504 <span type="species:ncbi:6277">Acanthocheilonema viteae</span>
###xml 579 590 <span type="species:ncbi:6282">O. volvulus</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 1192 1200 <span type="species:ncbi:9606">patients</span>
Studies in animal models have shown that Wolbachia-derived molecules from Brugia spp. induced proinflammatory cytokines, including TNF and IL-1B [38]. Soluble extracts of Brugia and Onchocerca volvulus adult and microfilarial worms were also found to stimulate human peripheral mononuclear cells in vitro, resulting in the production of TNF, IL-1, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-10 [39,40]. This stimulation was not achieved using extracts from Acanthocheilonema viteae, a filarial species naturally devoid of Wolbachia, and, importantly, with O. volvulus extracts from patients that had been treated with doxycycline to deplete Wolbachia from the worms [41]. Thus it was concluded that in those filarial species that contain these endosymbionts, Wolbachia are the major stimulating principle for proinflammatory cytokines such as TNF. From this it can be further hypothesized that exposure of host cells to Wolbachia from worms (either from dying adult worms or incoming L3/4 larvae, or from the proportion of degenerating embryos that are constantly released) may induce the production of lymphangiogenic factors such as VEGF-C by endothelial cells in LF patients.
###end p 12
###begin p 13
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b042">42</xref>
###xml 153 162 153 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 204 216 204 216 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">W. bancrofti</named-content>
###xml 221 232 221 232 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">O. volvulus</named-content>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b043">43</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b044">44</xref>
###xml 279 288 279 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b045">45</xref>
###xml 494 503 494 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 668 678 668 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia-</italic>
###xml 57 63 <span type="species:ncbi:9606">humans</span>
###xml 204 216 <span type="species:ncbi:6293">W. bancrofti</span>
###xml 221 232 <span type="species:ncbi:6282">O. volvulus</span>
###xml 758 763 <span type="species:ncbi:9606">human</span>
Treatment with doxycycline for 8 wk is well tolerated in humans and has shown macrofilaricidal activity [42]. Doxycycline is also effective in depleting Wolbachia from both MF and adult filarial worms of W. bancrofti and O. volvulus [43,44]. Of importance for the present study, Wolbachia depletion by doxycycline was associated with a reduction of pretreatment elevated levels of proinflammatory cytokines such as TNF from plasma [45]. Together, these data allow the hypothesis that targeting Wolbachia by doxycycline may ameliorate filarial pathology through down-regulation of proinflammatory cytokines and VEGF-C/VEGFR-3. However, no studies to date have analyzed Wolbachia-induced secretion of VEGF-C and its receptor on lymphatic vessel dilation among human populations with lymphatic filarial disease.
###end p 13
###begin p 14
###xml 148 157 148 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 853 862 853 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 492 500 <span type="species:ncbi:9606">patients</span>
###xml 593 601 <span type="species:ncbi:9606">patients</span>
###xml 658 666 <span type="species:ncbi:9606">patients</span>
###xml 1083 1091 <span type="species:ncbi:9606">patients</span>
The aims of this study were to assess (1) a 6-wk course of doxycycline for macrofilaricidal activity; (2) the effect of targeting the endosymbiotic Wolbachia in filarial worms on the levels of VEGF-C and its soluble receptor VEGFR-3 and on dilation of the supratesticular lymphatic vessels in microfilaremic patients; and (3) the effect of doxycycline treatment on clinical manifestations associated with filarial lymphedema. To address these aims, we recruited microfilaremic and lymphedema patients in an endemic area in Ghana and treated them with 200 mg/d doxycycline for 6 wk. Lymphedema patients were followed up at 4 and 12 mo, whereas microfilaremic patients were re-examined at 4, 12, and 24 mo after the start of doxycycline treatment. We report that 6 wk of doxycycline had a strong macrofilaricidal activity; and targeting the endosymbiotic Wolbachia in filarial worms resulted in the reduction of plasma levels of VEGF-C/sVEGFR-3, which were associated with amelioration of dilated supratesticular lymphatic vessels and improvement of lymphedema in lymphatic filariasis patients.
###end p 14
###begin title 15
Results
###end title 15
###begin p 16
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
###xml 722 730 <span type="species:ncbi:9606">patients</span>
###xml 852 859 <span type="species:ncbi:9606">patient</span>
We treated a total 95 patients with bancroftian filariasis (76 microfilaremic and 19 lymphedema) with doxycycline or matching placebo for 6 wk. The treatment was well tolerated, with eight doxycycline and ten placebo patients experiencing adverse reactions, which in no case required a treatment stop. The adverse reactions arose on days 2 and 3 after commencement of treatment in both groups. The adverse reactions experienced by the eight doxycycline-treated patients included headache, dizziness, diarrhea, and itching skin. No adverse event went beyond 3 d or required more intervention than application of paracetamol tablets, oral dehydration salt, and ointment. The adverse reactions experienced by the ten placebo patients included headache, diarrhea, and painful scrotum. Again no event lasted for more than 3 d, except for one microfilaremic patient who had a painful scrotum for 6 d. In this group, the side effects were also treated with paracetamol tablets and oral dehydration salt. There was no significant difference between the doxycycline and placebo groups.
###end p 16
###begin p 17
###xml 166 173 166 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t001">Table 1</xref>
###xml 454 462 454 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g001">Figure 1</xref>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g001">1</xref>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
###xml 248 260 <span type="species:ncbi:9606">participants</span>
###xml 380 388 <span type="species:ncbi:9606">patients</span>
Thirty-three (17 doxycycline and 16 placebo) microfilaremic patients and eighteen lymphedema patients (8 doxycycline and 10 placebo) were present at all time points (Table 1), and the analyses are based on these patients. In all the analyses, only participants present at all time points were included. Nonetheless, the significant differences observed were not affected when all patients (including the dropouts at the follow-up time points as shown in Figure 1A and 1B) were included in the analyses (unpublished data).
###end p 17
###begin title 18
###xml 43 51 <span type="species:ncbi:9606">Patients</span>
Primary Outcome Analysis in Microfilaremic Patients
###end title 18
###begin p 19
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t001">Table 1</xref>
###xml 29 38 29 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 268 277 268 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 408 409 408 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 148 160 <span type="species:ncbi:9606">participants</span>
Table 1 shows the changes in Wolbachia level, microfilaremia, and antigenemia from baseline and at follow-up time points. In all the analyses, only participants present at all time points (17 doxycycline and 16 placebo) were included. Following doxycycline treatment, Wolbachia levels in MF were reduced by 95% (p < 0.0001) in the doxycycline group, but there was no significant change in the placebo group (p = 0.2588).
###end p 19
###begin p 20
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 244 245 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 850 851 850 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 873 874 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
###xml 587 595 <span type="species:ncbi:9606">patients</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
###xml 938 946 <span type="species:ncbi:9606">patients</span>
Microfilaremia was only slightly, though not significantly, reduced 4 mo after doxycycline treatment compared to pretreatment levels in the doxycycline group (p = 0.2741) whereas microfilaria levels had actually increased in the placebo group (p = 0.0017). Both doxycycline and placebo patients were given albendazole and ivermectin after the 4 mo re-examination to clear microfilaremia. At 12 mo post therapy, microfilaremia was virtually absent in the doxycycline group except in one of the 17 (6%) patients, who had a very low MF count. At 24-mo follow-up, 18% of doxycycline-treated patients that were re-examined had microfilaremia. In contrast, 50% of placebo patients became microfilaremic at 12 mo, and the number increased to 63% at 24 mo. The reduction of MF in the doxycycline group compared to placebo group was significant at the 12 mo (p = 0.0029) and 24 mo (p = 0.0211) follow-up time points. It must be mentioned that all patients continued to live in the endemic area; given a 5-y average life-span of adult worms and constant worm loads without treatment interference, new infections are expected to occur at a rate of about 20% per year.
###end p 20
###begin title 21
###xml 53 61 <span type="species:ncbi:9606">Patients</span>
Measurement of Adult Worm Vitality in Microfilaremic Patients
###end title 21
###begin p 22
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 289 290 289 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 382 383 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 474 481 474 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t001">Table 1</xref>
###xml 1116 1118 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b046">46</xref>
###xml 1883 1884 1883 1884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1984 1985 1984 1985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1995 2002 1995 2002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t001">Table 1</xref>
###xml 30 33 <span type="species:ncbi:31658">CFA</span>
###xml 181 184 <span type="species:ncbi:31658">CFA</span>
###xml 407 410 <span type="species:ncbi:31658">CFA</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 734 742 <span type="species:ncbi:9606">patients</span>
###xml 887 895 <span type="species:ncbi:9606">patients</span>
###xml 1083 1091 <span type="species:ncbi:9606">patients</span>
###xml 1201 1206 <span type="species:ncbi:9606">women</span>
###xml 1279 1287 <span type="species:ncbi:9606">patients</span>
###xml 1373 1381 <span type="species:ncbi:9606">patients</span>
###xml 1475 1483 <span type="species:ncbi:9606">patients</span>
###xml 1612 1620 <span type="species:ncbi:9606">patients</span>
###xml 1722 1730 <span type="species:ncbi:9606">patients</span>
Circulating filarial antigen (CFA) levels in plasma, and presence or absence of worm nests in ultrasound examinations, were used to assess macrofilaricidal activity of doxycycline. CFA did not differ significantly between the two groups before and at 12 mo after treatment (p = 0.5718 and p = 0.1748, respectively). However, the difference became significant at 24 mo post therapy (p = 0.0382), with median CFA levels in the doxycycline group being only 6% of pretreatment (Table 1). Before doxycycline treatment, all the 33 (17 doxycycline and 16 placebo) patients had antigenemia levels higher than 32,000 units (highest titer ranking according to the manufacturer, TropBio). However, 5/17 (29%) and 11/17 (65%) doxycycline-treated patients had antigen units lower than the 32,000 units at 12 and 24 mo, respectively, after treatment, whereas only 3/16 (19%) and 4/16 (25%) of placebo patients had antigens lower than 32,000 units at these time points. Ultrasonography to detect the filarial dance sign (FDS) as a second parameter of adult worm vitality was performed only in male patients since our earlier data [46] had shown that the FDS is detected less frequently and probably less reliably in women. FDS in the scrotal region before treatment showed that nine of 13 male patients examined in the doxycycline group had between 1-4 worm nests, whereas ten of 11 male patients in the placebo group had worm nests ranging from 1-5 worm nests. Considering only those male patients who had detectable FDS before treatment (nine doxycycline and ten placebo), 67% (6/9) and 89% (8/9) of male doxycycline-treated patients became FDS-negative at 12 and 24 mo after treatment, respectively. In contrast, all ten male placebo patients remained FDS-positive at 12 mo and 20% (2/10) were FDS-negative at 24 mo post therapy. There was no difference between the two groups before treatment (p = 0.3271); however, the difference became significant at 12 and 24 mo after doxycycline treatment (p < 0.001, Table 1).
###end p 22
###begin title 23
###xml 46 54 <span type="species:ncbi:9606">Patients</span>
Secondary Outcome Variables in Microfilaremic Patients
###end title 23
###begin title 24
Dilation of supratesticular lymphatic vessels.
###end title 24
###begin p 25
###xml 173 181 173 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g002">Figure 2</xref>
###xml 186 193 186 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t002">Table 2</xref>
###xml 420 421 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 487 488 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 665 666 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 677 684 677 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t002">Table 2</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
Before doxycycline treatment, ultrasonography (USG) showed that 17 male patients (nine doxycycline and eight placebo-treated) had supratesticular lymphatic vessel dilation. Figure 2 and Table 2 illustrate changes, after doxycycline treatment, in the dilation of lymph vessels that had not contained worms at study onset. Dilated lymphatic vessels containing no worms were reduced significantly at 24 mo after treatment (p = 0.0404) in the doxycycline group but not in the placebo group (p = 0.2168). Of the nine doxycycline-treated patients, seven (78%) patients showed a reduction of the lymphatic vessels in comparison to 1/8 (13%) patients in the placebo group (p = 0.0319, Table 2). In addition, lymphatic vessels that had contained adult worms at study onset were also reduced to normal in the doxycycline group at 24 mo.
###end p 25
###begin title 26
Incidence of hydrocele during the 24-mo observation period.
###end title 26
###begin p 27
###xml 657 658 657 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 222 229 <span type="species:ncbi:9606">patient</span>
###xml 313 320 <span type="species:ncbi:9606">patient</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
In support of the hypothesis that doxycycline can ameliorate lymphatic vessel alteration, more patients in the placebo group developed a hydrocele during the observation period compared to the doxycycline group. Thus, one patient in the doxycycline-treated group developed a clinical hydrocele whereas in another patient, the hydrocele disappeared. In contrast, in the placebo-treated group, five patients developed hydrocele (three subclinical, as assessed by USG, and two clinical). This increase of hydrocele in the placebo group was significant when compared to the pretreatment status (hydrocele positive/negative at pretreatment: 1/10; at 24 mo: 6/5, p = 0.0221, chi-square test).
###end p 27
###begin title 28
Lymphangiogenic factors.
###end title 28
###begin p 29
###xml 124 125 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 136 144 136 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g003">Figure 3</xref>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 162 170 162 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g004">Figure 4</xref>
###xml 334 355 334 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 478 486 478 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g005">Figure 5</xref>
###xml 725 726 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 737 745 737 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g006">Figure 6</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 813 821 <span type="species:ncbi:9606">patients</span>
###xml 931 939 <span type="species:ncbi:9606">patients</span>
Mean plasma concentrations of VEGF-C and soluble VEGFR-3 (sVEGFR-3) were significantly elevated in microfilaremic patients (p < 0.0001, Figure 3, and p = 0.0006, Figure 4, respectively) compared to endemic controls, i.e., residents of the same endemic area with no evidence of infection despite exposure to infective larvae (see also Materials and Methods). Following doxycycline treatment, mean values of VEGF-C in the doxycycline group were significantly reduced (p = 0.0198, Figure 5), whereas there was no significant reduction in the placebo group. Mean plasma values of sVEGFR-3 in the doxycycline group were also significantly reduced 12 mo after doxycycline treatment to a level close to that of the endemic normals (p = 0.0125, Figure 6). In contrast, mean levels remained almost the same in the placebo patients. Samples from 24 mo post therapy were not sufficient in volume for VEGF-C and sVEGFR-3 analysis because most patients refused to donate the usual 10 ml of venous blood.
###end p 29
###begin title 30
Associations between plasma levels of growth factors and parasitological parameters.
###end title 30
###begin p 31
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 360 361 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 442 443 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 520 521 520 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 546 547 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Using pretreatment samples, we found a positive correlation between VEGF-C and sVEGFR-3 (r = 0.430, p = 0.0014). No correlation was found between VEGF-C and lymphatic dilation, but a strong trend (r = 0.390, p = 0.0514) was noticed between sVEGFR-3 and lymphatic vessel dilation. There was also a positive association between levels of VEGF-C and antigenemia (r = 0.434, p < 0.0001) and between levels of sVEGFR-3 and antigenemia (r = 0.367, p = 0.0065), but no associations between microfilaremia and levels of VEGF-C (p = 0.8864) and sVEGFR-3 (p = 0.7720) were found.
###end p 31
###begin title 32
###xml 39 47 <span type="species:ncbi:9606">Patients</span>
Primary Outcome Analysis in Lymphedema Patients
###end title 32
###begin title 33
###xml 0 3 <span type="species:ncbi:31658">CFA</span>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
CFA and antifilarial antibody titers of lymphedema patients.
###end title 33
###begin p 34
###xml 47 55 47 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g001">Figure 1</xref>
###xml 291 299 291 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g001">Figure 1</xref>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 118 125 <span type="species:ncbi:9606">patient</span>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
###xml 332 335 <span type="species:ncbi:31658">CFA</span>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
###xml 416 419 <span type="species:ncbi:31658">CFA</span>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
###xml 583 590 <span type="species:ncbi:9606">patient</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
Twenty-six lymphedema patients were recruited (Figure 1B), and 19 met the inclusion criteria. Of the 19 patients, one patient was absent at 12 mo, leaving 18 patients who were present before and 12 mo after treatment. Of the 18 patients, eight received doxycycline and ten received placebo (Figure 1B). All lymphedema patients were CFA-positive except two (one doxycycline- and one placebo-treated) patients who had CFA levels below the cut-off of 128 units/ml; these two patients however had positive filarial antibody titers (all subclasses are measured in this test). One placebo patient was microfilaremic. All 18 patients had filarial antibody titers (1:40-1:640).
###end p 34
###begin p 35
###xml 197 204 197 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t003">Table 3</xref>
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 439 440 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
There were reductions in the antigenemia levels in both doxycycline and placebo patients with lymphedema at 12 mo, but no significant difference in the reduction was obtained in any of the groups (Table 3) at this time point. The antibody levels were significantly reduced in the doxycycline-treated group compared to pretreatment (p = 0.0431, Wilcoxon rank test), whereas there was no significant difference in the placebo-treated group (p = 0.0935, Wilcoxon rank test).
###end p 35
###begin title 36
Stages of lymphedema.
###end title 36
###begin p 37
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t003">Table 3</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b047">47</xref>
###xml 479 480 479 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
###xml 562 570 <span type="species:ncbi:9606">patients</span>
Table 3 shows the changes in the lymphedema stage-determined according to the staging scheme by Dreyer et al. [47]-of the affected legs and the circumference of the affected legs from baseline and 12 mo after treatment. The affected legs of all the doxycycline-treated patients reverted to a lower lymphedema stage at 12 mo post therapy, whereas all the placebo-treated patients stayed the same or changed to a higher stage at this time point. There was a significant reduction (p = 0.0051, Wilcoxon rank test) in the lymphedema stage of the doxycycline-treated patients at 12 mo post therapy compared to pretreatment, but not in the placebo group). The reduction in the stage manifested as better skin integrity (fewer "knobs"), reduction of deep and shallow skin folds, and fewer entry lesions of the affected legs (not shown). No change in the mean circumference of the affected legs in both doxycycline and placebo groups at 12 mo post therapy was observed.
###end p 37
###begin title 38
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Lymphangiogenic factors of lymphedema patients.
###end title 38
###begin p 39
###xml 51 60 51 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g003">Figures 3</xref>
###xml 65 66 65 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g004">4</xref>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 136 137 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 338 339 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 350 358 350 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g004">Figure 4</xref>
###xml 496 497 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 508 516 508 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g007">Figure 7</xref>
###xml 522 523 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 534 542 534 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g008">Figure 8</xref>
###xml 853 854 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
Mean plasma concentrations of VEGF-C and sVEGFR-3 (Figures 3 and 4) were significantly elevated in lymphedema patients (p = 0.0002, and p = 0.0012, respectively) compared to endemic controls. Interestingly, the plasma levels of sVEGFR-3 were significantly higher in lymphedema patients than in microfilaremic patients without lymphedema (p = 0.0024, Figure 4). Twelve months following doxycycline treatment, mean values of VEGF-C and sVEGFR-3 in the doxycycline group were significantly reduced (p = 0.0499, Figure 7, and p = 0.0251, Figure 8, respectively), whereas there were no significant alterations in the placebo group. Since the pretreatment standard deviation of the sVEGFR-3 levels in the doxycycline group was rather large, due to one very high value, we also applied the Wilcoxon test in this case; there was still a significant difference (p = 0.0284) in sVEGFR-3 levels between pretreatment and 12 mo.
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
The past decade has seen major advances that have changed LF from a neglected disease into a disease now accepted as potentially eradicable. The main reason is the identification of ivermectin, DEC, and albendazole, as effective antifilarial agents.
###end p 41
###begin p 42
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b048">48</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b049">49</xref>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b050">50</xref>
While DEC has been shown to have some macrofilaricidal effect, it is still believed that a more potent macrofilaricide will add to efforts to achieve LF elimination, halting also the progression of the clinical manifestations induced largely by the adult worm [48]. This particularly is the case for Africa, where the use of DEC is discouraged in areas co-endemic for onchocerciasis, due to the irreversible ocular damage that DEC induces, different from ivermectin [49,50].
###end p 42
###begin p 43
###xml 103 116 103 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">W. bancrofti,</italic>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b042">42</xref>
###xml 171 180 171 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 103 115 <span type="species:ncbi:6293">W. bancrofti</span>
###xml 360 372 <span type="species:ncbi:9606">participants</span>
Two major advances have been observed in this study. Firstly, a regimen of 6 wk of doxycycline against W. bancrofti, shorter than what we published earlier [42], depleted Wolbachia endosymbionts and showed a strong macrofilaricidal activity, as evidenced by reduction of antigenemia by 94% and the absence of adult worms from the scrotal region in 89% of male participants by USG 24 mo after treatment. The second and fully novel advance is the reduction of lymphangiogenetic factors following doxycycline, and the reduction of lymphatic vessel dilation and improvement of lymphedema.
###end p 43
###begin title 44
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
Wolbachia Load
###end title 44
###begin p 45
###xml 31 40 31 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 242 251 242 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 628 637 628 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 791 800 791 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 907 916 907 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 918 920 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b051">51</xref>
###xml 1236 1238 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b044">44</xref>
###xml 1328 1337 1328 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 1465 1467 1465 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b052">52</xref>
###xml 1468 1470 1468 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b053">53</xref>
###xml 1498 1500 1498 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b042">42</xref>
###xml 1501 1503 1501 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b044">44</xref>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
###xml 579 587 <span type="species:ncbi:9606">patients</span>
###xml 1283 1291 <span type="species:ncbi:9606">patients</span>
We recorded a 95% reduction of Wolbachia load in doxycycline-treated patients 4 mo after treatment, and this reduction was sustained throughout the 24-mo follow-up period. The fact that there was an apparent, but not significant, increase in Wolbachia loads in three MF-positive doxycycline patients at 24 mo is probably due to new infections, which is likely to occur in this area of ongoing transmission, theoretically at a yearly rate of 20% of the total worm load, given that the average worm life span is about 5 y and that there is a rather stable adult worm load in adult patients. New infections with concurrent rise in Wolbachia levels following doxycycline treatment have already been documented for doxycycline treatment of onchocerciasis, where old, doxycycline-treated and thus Wolbachia depleted, female worms were located in onchocercomas next to young, nulliparous worms that were full with Wolbachia [51]. Due to the unavailability of adult worms for histological and PCR analysis in LF, we could not formally confirm these findings for LF. Doxycycline treatment also resulted in almost complete elimination of microfilaremia which was sustained throughout the 24-mo period. This is consistent with our previous study [44]. The loss of microfilaremia in doxycycline patients is most likely due to the effect of Wolbachia depletion on embryogenesis and loss of microfilariae from host blood through natural attrition, as recorded in onchocerciasis [52,53] and lymphatic filariasis [42,44].
###end p 45
###begin title 46
Antigenemia
###end title 46
###begin p 47
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b054">54</xref>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
###xml 906 914 <span type="species:ncbi:9606">patients</span>
Even though antigenemia levels were significantly reduced by 94% in doxycycline-treated microfilaremic as compared to 48% in placebo patients, antigen units remained elevated at 24 mo in some doxycycline patients, though USG results showed the absence of worm nests. Before doxycycline treatment, all 33 (17 doxycycline and 16 placebo) patients had antigenemia levels above 32,000 units (the highest level that can be semiquantitatively determined according to the manufacturer, TropBio). However, at 24 mo, 11/17 (65%) of doxycycline-treated patients had antigen units below 32,000, compared to only 4/16 (25%) of placebo patients. Given that USG demonstrated absence of worm nests in most doxycycline-treated patients analyzed, our data suggest that antigenemia is cleared from the blood slowly, but progressively, after the death of the adult worms, as suggested by others [54]. The lower proportion of patients with high antigenemia in the doxycycline group underscores this and shows that it probably takes more than 24 mo for the antigens to be cleared from the blood after the death of the adult worms.
###end p 47
###begin p 48
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b055">55</xref>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b057">57</xref>
###xml 1004 1005 1004 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1015 1016 1015 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1067 1069 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b058">58</xref>
###xml 1585 1587 1585 1587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b047">47</xref>
###xml 1588 1590 1588 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b048">48</xref>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 884 892 <span type="species:ncbi:9606">patients</span>
###xml 1407 1415 <span type="species:ncbi:9606">patients</span>
###xml 1518 1526 <span type="species:ncbi:9606">patients</span>
###xml 1640 1648 <span type="species:ncbi:9606">patients</span>
We cannot exclude that the partial reduction in antigenemia observed in the placebo patients could be due, to some extent, to a partial macrofilaricidal effect of ivermectin plus albendazole treatment. USG results did show 20% loss of worm nests at 24 mo; however, this reduction did not reach statistical significance. The lack of significance could be due to the rather small number of placebo patients (n = 16); however, even if a significant difference had been detected with higher numbers, the extent of the reduction would not have increased. Thus, our findings rather support other reports that ivermectin plus albendazole has no significant macrofilaricidal effect [55-57]. Another explanation that probably accounts for more of the reduction of antigenemia in the placebo group is the depletion of microfilaremia as a result of the antifilarial treatment offered to all the patients at the 4-mo time point. In this study, we found a positive correlation between microfilaremia and antigenemia (r = 0.754, p < 0.0001). This is consistent with another study [58] in which a positive correlation between microfilaremia and antigenemia was also reported, implying that as MF in the blood are depleted, the level of antigenemia also goes down, hence the reduction seen at 12 and 24 mo after treatment in the placebo group. A significant macrofilaricidal effect of ivermectin and albendazole in placebo patients is, however, not supported by the USG results, which demonstrated mostly stable worm nests in placebo patients (confirming earlier results by Dreyer et al. and others) [47,48], in contrast to most of the doxycycline-treated patients.
###end p 48
###begin title 49
VEGF Levels
###end title 49
###begin p 50
###xml 501 508 501 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t002">Table 2</xref>
###xml 510 518 510 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g002">Figure 2</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b059">59</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b060">60</xref>
###xml 1086 1088 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b036">36</xref>
###xml 1232 1234 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b061">61</xref>
###xml 1455 1457 1455 1457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b062">62</xref>
###xml 1505 1507 1505 1507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b063">63</xref>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 1121 1127 <span type="species:ncbi:10090">murine</span>
Apart from the macrofilaricidal effect by doxycycline, the second observation in this study is that plasma levels of VEGF-C and its soluble receptor, sVEGFR-3, are significantly elevated in patients infected with filarial worms, and there is a correlation between sVEGFR-3 and lymphatic dilation. Targeting the filarial worms by doxycycline reduces the levels of VEGF-C/sVEGFR-3, with amelioration of dilated supratesticular lymphatic vessels and improvement in the conditions of lymphedema patients (Table 2, Figure 2). Given that the sVEGFR-3 are secreted into the plasma following overstimulation of the lymphangiogenesis system [59,60], these data indicate that the stimulation of lymphangiogenesis followed by lymphatic dilation may be reduced by doxycycline, and the VEGF-C/VEGFR-3 system may constitute a major mediator of pathological lymphatic dilation. This may be similar to what pertains in animal models in which inhibition of the binding of VEGF-C to membrane-bound VEGFR-3 by sVEGFR-3 led to complete destruction of the lymphatic network and a lymphedema-like phenotype [36]. Recent studies in solid tumor murine models have also correlated increased tumor-derived VEGF-C with lymphangiogenesis and lymph metastasis [61], supporting a role of VEGF-C in tumor progression by acting on lymphatic endothelium. It has also been shown that VEGFR-3 and its ligand VEGF-C are up-regulated in several diseases such as AIDS-linked Kaposi's sarcoma [62] and tumor lymphangiogenesis in breast cancer [63].
###end p 50
###begin p 51
###xml 1542 1544 1542 1544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b064">64</xref>
###xml 1667 1669 1667 1669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b065">65</xref>
###xml 419 425 <span type="species:ncbi:9606">people</span>
###xml 492 499 <span type="species:ncbi:9606">persons</span>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
###xml 815 823 <span type="species:ncbi:9606">patients</span>
###xml 856 864 <span type="species:ncbi:9606">patients</span>
###xml 1601 1609 <span type="species:ncbi:9606">patients</span>
###xml 1768 1776 <span type="species:ncbi:9606">patients</span>
###xml 1868 1876 <span type="species:ncbi:9606">patients</span>
The mean plasma level of VEGF-C given by the manufacturer of Quantikine immunoassay enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Wiesbaden, Germany) in a cohort of healthy European individuals is 225 (185-1,231) pg/ml. The levels of endemic normals in the present study was somewhat higher, with a mean of 1,851 pg/ml (range 634-2,805); it is not clear whether this reflects genetic differences between people of European descent and Africans, or a possible exposure of these persons to stimuli of the lymphangiogenetic system other than lymphatic filariasis. However, the levels of VEGF-C in microfilaremic and lymphedema patients were significantly increased over those of endemic normals before treatment. This finding, and more so the yet significantly elevated levels of sVEGFR-3 in lymphedema patients in comparison to microfilaremic patients (e.g., those with filarial infection but without overt lymphatic pathology), raises the question about the biological significance. Despite a vast literature on VEGF-C or sVEGFR3 expression in tissue (quantitative PCR and immunohistology), few data on plasma exist for these two factors, which are the major axis specific for lymphangiogenesis. What can be concluded from the available data are the following: (1) serum levels of VEGF-C are usually 10-fold higher than plasma levels, because of release from platelets during coagulation; this also means that plasma levels would be the more reliable marker since there is no (dominant) interference by platelet-derived VEGF-C [64]; and (2) measurement of plasma VEGF-C levels in cancer patients revealed 3-fold higher levels in comparison to controls [65]. In this regard, it is assumed that the almost 3-fold increase of plasma VEGF-C levels in our LF patients over endemic normals would be biologically significant based on the comparison with cancer patients. Importantly, in our study, VEGF-C levels decreased by 12 mo after doxycycline treatment, well before the supratesticular lymphatic dilation improved. The fact that the VEGF-C reduction preceded the improvement of pathology indicates a possible causal interaction between lymphangiogenic factors reduced by doxycycline treatment and lymphatic pathology, rather than only a coincidence or an epiphenomenon.
###end p 51
###begin p 52
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b066">66</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
A report on VEGF-C levels in cervical cancer patients provides levels in serum, not plasma, and is therefore not directly comparable to our data (see the constraints above); nevertheless, in that report, after anticancer therapy the levels decreased to the level of controls, accompanied by concomitant improvement in the conditions of the patients [66], as also observed in our study in which levels decreased to those of endemic normals following doxycycline treatment.
###end p 52
###begin p 53
###xml 172 180 <span type="species:ncbi:9606">patients</span>
Unfortunately no data exist as yet with regard to plasma sVEGFR3 levels and their biological significance for tumors. However, the more than 3-fold elevation in lymphedema patients is not considered to be biologically meaningless.
###end p 53
###begin title 54
Supratesticular Lymphatic Dilation
###end title 54
###begin p 55
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b067">67</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b068">68</xref>
###xml 234 239 <span type="species:ncbi:9606">human</span>
The degree of lymphatic dilation caused by filarial worms is considered an indirect measurement of the altered lymphatic function [67]. One study suggests that diffusible secretory products released either by the adult worm or by the human host in response to the parasite may induce lymphatic dilation [68]. Here, we have provided circumstantial evidence for both, in a series of events: the lymphatic dilation may be partly caused by overexpression of VEGF-C/sVEGFR-3 produced by the endothelial cells of the lymphatic vessels of the host in response to products of the adult worm that are reduced by doxycycline. Importantly, the reduction of dilated vessels was not mechanical as a result of the death of the adult worms, since the dilated vessels that were analyzed for this purpose did not contain worm nests.
###end p 55
###begin p 56
###xml 201 210 201 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 312 321 312 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b045">45</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b045">45</xref>
###xml 638 647 638 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b045">45</xref>
###xml 293 298 <span type="species:ncbi:9606">human</span>
The mechanism of action of doxycycline on the reduction of VEGF-C/sVEGFR-3 and its ameliorating effect on lymphatic vessel is not yet fully clarified. However, this may be associated with depletion of Wolbachia from adult filarial worms in the lymphatic vessels. There are now valid data from human studies that Wolbachia stimulate proinflammatory cytokines such as TNF, IL-1B, IL-6, and nitric oxide [45], which are known to up-regulate the expression of VEGF-C; importantly, these cytokines are down-regulated after doxycycline treatment [45]. This raises the possibility that proinflammatory cytokines such as TNF and IL-1B induced by Wolbachia could affect lymphatic vessels via VEGF-C and its receptor sVEGFR-3. It is therefore conceivable that any therapeutic intervention that causes reduction of VEGF-C-inducing proinflammatory cytokines such as TNF, IL-1B [45], etc. would be able to reduce levels of VEGF-C/sVEGFR-3, and hence lead to reduction of dilated supratesticular lymphatic vessels as we have shown here.
###end p 56
###begin p 57
###xml 149 157 <span type="species:ncbi:9606">patients</span>
In this regard, it is remarkable that there was a significant increase in the prevalence of hydroceles in placebo as compared to doxycycline treated patients in our study.
###end p 57
###begin title 58
Lymphedema Stages
###end title 58
###begin p 59
###xml 832 833 832 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b008">8</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b010">10</xref>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b069">69</xref>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b070">70</xref>
###xml 1055 1056 1055 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b008">8</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b069">69</xref>
###xml 1060 1062 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b070">70</xref>
###xml 1492 1494 1492 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b047">47</xref>
###xml 1672 1674 1672 1674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b047">47</xref>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
###xml 719 727 <span type="species:ncbi:9606">patients</span>
###xml 752 760 <span type="species:ncbi:9606">patients</span>
###xml 1238 1246 <span type="species:ncbi:9606">patients</span>
Doxycycline treatment significantly reduced the stage of disease in lymphedema patients, whereas the stage was not significantly altered in placebo patients, who, rather, showed a trend towards deterioration. The improvement in the stage in doxycycline patients manifested as better skin texture, fewer deep folds, and also fewer entry lesions of the affected legs (unpublished data). This suggests that doxycycline can be used to improve the clinical manifestations of lymphedema due to filariasis. A reduction of the number of adenolymphangitis (ADL) attacks that was noted in both, doxycycline and placebo patients (unpublished data) could be attributed to the foot-care hygiene training given to all the lymphedema patients, and with an attempt by patients to demonstrate best compliance. This is consistent with other reports [8,10,69,70], which also showed a significant reduction of attacks due to foot-care hygiene. However, a combination of foot-care hygiene and DEC gave no additional benefits regarding an improvement of the lymphedema stages [8,69,70]. This confirms that local limb care is an important intervention, whereas addition of doxycycline further reduces the severity of lymphedema. Neither doxycycline nor placebo patients showed a significant reduction of the circumference of the affected legs. This may be due to the fact that that circumference determination is not a reliable parameter to assess improvement of the disease, as suggested by Dreyer and co-workers [47], since it shows considerable variability due to transient effects such as keeping the leg elevated in the hours before measurement, or the female monthly hormonal cycle, etc. [47].
###end p 59
###begin p 60
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b071">71</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b072">72</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b073">73</xref>
Clinical manifestations of lymphedema do not only hasten the progression of lymphedema to elephantiasis [71], but also reduce the workforce and economic resources of the affected individuals and communities [72,73] in many endemic areas. Therefore, better treatment options are mandatory.
###end p 60
###begin p 61
###xml 227 236 227 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b074">74</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b075">75</xref>
The current treatment of lymphedema, which mainly relies on foot hygiene, is suboptimal and still empirical. This is because it is not clear at present to which extent ADL attacks are caused by either filarial worms, including Wolbachia endosymbionts, by exogenous bacteria, or by both [74,75].
###end p 61
###begin p 62
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b076">76</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b077">77</xref>
###xml 314 323 314 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b008">8</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b008">8</xref>
###xml 727 736 727 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 909 919 909 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia,</italic>
###xml 1172 1174 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b078">78</xref>
###xml 1532 1534 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b021">21</xref>
###xml 1054 1062 <span type="species:ncbi:9606">patients</span>
###xml 1075 1078 <span type="species:ncbi:31658">CFA</span>
###xml 1161 1169 <span type="species:ncbi:9606">patients</span>
###xml 1373 1381 <span type="species:ncbi:9606">patients</span>
###xml 1609 1612 <span type="species:ncbi:31658">CFA</span>
###xml 1657 1660 <span type="species:ncbi:31658">CFA</span>
###xml 1681 1689 <span type="species:ncbi:9606">patients</span>
Several chemotherapeutic agents have been tested, but so far, only 5,6 benzo-alpha-pyrone (coumarin) showed some encouraging results [76]. However, this drug is no longer recommended since it has been shown to be hepatotoxic [77]. Penicillin, which acts on some exogenous bacteria such as streptococci, but not on Wolbachia endosymbionts, has also been tested and reported to be beneficial in reducing only the incidence of ADL attacks [8], but there was no significant reduction in the lymphedema stages [8]. In contrast, in our study, treatment with doxycycline led to a significant amelioration of lymphedema stages. This could be due to the fact that doxycycline, in addition to targeting exogenous bacteria, also targeted Wolbachia endosymbionts and reduced lymphangiogenic factors along with a reversion of lymph vessel dilation. In order for doxycycline to exert its ameliorating activity by targeting Wolbachia, it is mandatory that the targets, i.e., adult worms or at least incoming L3/4 larvae, are present in the host's body. Indeed, all our patients were either CFA-positive (although most they did not exhibit high levels, as known for lymphedema patients) [78], or they showed clearly positive antifilarial antibody titers as a sign of recent exposure (two cases), in accordance with the assumption that it is a characteristic feature of lymphedema that the patients have a strong immune reaction that is targeted to incoming L3 and L4 larvae, effectively killing them, however at the expense of strong inflammation [21]. Studies are currently ongoing to compare the efficacy of doxycycline in CFA-positive in comparison to a larger group of CFA-negative lymphedema patients.
###end p 62
###begin p 63
###xml 11 19 <span type="species:ncbi:9606">patients</span>
Lymphedema patients have a high level of suffering, and it can be well expected that they would use doxycycline for 6 wk without the need of a directly observed treatment (DOT). This is so all the more since the current mass treatment does not improve lymphedema per se. Hence, doxycycline treatment will have a good chance to be the first chemotherapeutic approach to address lymphatic pathology.
###end p 63
###begin p 64
###xml 403 412 403 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b071">71</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b079">79</xref>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b080">80</xref>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b081">81</xref>
###xml 818 820 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b081">81</xref>
###xml 921 922 921 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b008">8</xref>
###xml 1012 1021 1012 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 305 308 <span type="species:ncbi:31658">CFA</span>
###xml 760 768 <span type="species:ncbi:9606">patients</span>
###xml 876 884 <span type="species:ncbi:9606">patients</span>
In conclusion, our data are in agreement with the hypothesis that progression of infection to lymphedema may be due to overexpression of lymphangiogenic factors such as VEGF-C and more so, sVEGF-R3, first due to the presence or the death of adult filarial worms in the lymphatic vessels and later (in the CFA-negative phase of the disease) either by the incoming larval stages of the parasite releasing Wolbachia upon being killed, or (additionally) by skin commensals such as streptococci [71,79,80] that exacerbate the condition by stimulating more proinflammatory cytokines and VEGF molecules, which are also reduced by doxycycline. This hypothesis is further supported by another study [81] in which the level of serum VEGF was shown to remain the same in patients with bancroftian filariasis after DEC treatment [81], which does not have beneficial effects on lymphedema patients apart from reducing parasite loads [8]. This is probably due to the fact that DEC treatment has no effect on bacteria (neither Wolbachia nor exogenous species), and therefore has no effect on proinflammatory cytokines that regulate this VEGF family, although it does partially reduce adult worm levels.
###end p 64
###begin p 65
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 238 246 238 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g004">Figure 4</xref>
###xml 1208 1210 1208 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b082">82</xref>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 961 969 <span type="species:ncbi:9606">children</span>
###xml 1048 1053 <span type="species:ncbi:9606">human</span>
###xml 1245 1253 <span type="species:ncbi:9606">patients</span>
Although both microfilaremic and lymphedema patients had elevated VEGF-C and sVEGFR-3 levels, those of sVEGFR-3 were yet significantly higher in lymphedema patients compared to non-lymphedema patients that are microfilaremic (p = 0.0024, Figure 4). This could be an indication that plasma levels of VEGF-C/sVEGFR-3 may correlate with disease progression in LF leading to lymphatic dilation and lymphedema development and hence, might be developed as prognostic indicators of an increased risk of LF pathology before it actually becomes manifest. Importantly, reduction of lymphangiogenic factors preceded the improvement in pathology. On the one hand, these data argue against a possible hypothesis that elevated levels of these factors merely reflect infection. On the other, they do offer a potential to identify individuals who are prone to develop more severe disease. For this, a prospective study is needed that would screen VEGF-C and sVEGFR-3 levels in children and young adults, and monitor development of pathology such as lymphedema. In human studies of lymphedema families, heterozygous inactivating missense mutations have been detected in the tyrosine kinase-encoding region of Flt4 (VEGFR-3) [82], indicating that some lymphedema patients have dysfunctional lymphatics due to defective VEGFR-3 signaling. This might also be exploited for the development of an early marker for lymphedema.
###end p 65
###begin p 66
###xml 584 592 <span type="species:ncbi:9606">patients</span>
Considering the possible effect of VEGF-C/sVEGFR-3 on lymphatic dilation and lymphedema development, a combination of classical antifilarial plus antiwolbachial therapy, which will reduce production of proinflammatory cytokines, may prove to be more effective in treating pathogenesis associated with LF than antifilarial therapy alone. This study represents a first observation that antiwolbachial therapy does not only have macrofilaricidal activity but may also halt progression of manifestations associated with lymphatic filariasis, and have a potential restorative effect on LF patients. As discussed earlier, compliance to take doxycycline for extended periods is not expected to be an issue with individuals suffering from lymphatic pathology.
###end p 66
###begin title 67
Materials and Methods
###end title 67
###begin p 68
###xml 170 175 <span type="species:ncbi:9606">Human</span>
This placebo-controlled, double-blind study was carried out in the Nzema East District in the Western region of Ghana. The study was approved by the Ethical Committee on Human Research and Ethics of the School of Medical Sciences of Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana, as well as by the ethics committee of the University of Liverpool which acted as a control body since this work formed part of a European study network funded by the European Commission. The study conformed to the principles of the Helsinki Declaration of 1975 (as revised in 1983 and 2000). The trial registration number is ISRCTN 14757.
###end p 68
###begin title 69
Study population.
###end title 69
###begin p 70
###xml 255 263 255 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g001">Figure 1</xref>
###xml 312 320 312 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g001">Figure 1</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b044">44</xref>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 641 653 <span type="species:ncbi:9606">participants</span>
###xml 1018 1026 <span type="species:ncbi:9606">patients</span>
Individuals enrolled from the neighboring villages of Adjan, Domunli, and Akonu in the Western Region of Ghana took part in the study. No other human filarial species were endemic in these villages. A total of 76 (55 males and 21 females) microfilaremic (Figure 1A) and 19 (13 females and six males) lymphedema (Figure 1B) patients were included in this study. The study site was selected based on an established occurrence of lymphatic filariasis within the surrounding region and clinical observations (rapid assessment) consistent with symptomatic disease in a proportion of villagers [44]. Written informed consent was obtained from all participants. Individuals eligible for participation were adults of both sexes aged 18-50 y, with a minimum body weight of more than 40 kg, in good health, and without any clinical condition requiring chronic medication. Hepatic and renal function and pregnancy were assessed by dipstick chemistry. Exclusion criteria encompassed a microfilarial load <50 MF/ml (microfilaremic patients), abnormal hepatic and renal enzymes (aspartate aminotransferase [AST; 0-40 IU/l], alanine aminotransferase [ALT; 0-45 IU/l] and creatinine [3-126 mumol/l]), pregnancy, lactation, intolerance to doxycycline, alcohol or drug abuse, or antifilarial therapy in the last 10 mo.
###end p 70
###begin title 71
###xml 17 25 <span type="species:ncbi:9606">patients</span>
Randomization of patients and treatment regimens.
###end title 71
###begin p 72
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 143 150 <span type="species:ncbi:9606">persons</span>
Randomization of patients was carried out using computer-generated random number software (StatView). Blinding was assured by the exclusion of persons involved in randomization or tablet packaging in any clinical or laboratory assessment.
###end p 72
###begin p 73
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 336 348 <span type="species:ncbi:9606">participants</span>
Participants received 2 x 100 mg capsules of doxycycline (Vibramycin; Pfizer, New York, New York, United States) or matching placebo supplied by the manufacturer daily for a total of 6 wk. Treatment was done and monitored by a trial clinician in the form of daily observed treatment (DOT). Four months after the start of treatment, all participants received a standard oral dose of 400 mg albendazole (GlaxoSmithKline, Uxbridge, United Kingdom) and 150-200 mug/kg ivermectin (Mectizan; Merck, Sharp & Dohme, Clermont-Ferrand, France).
###end p 73
###begin title 74
USG examinations.
###end title 74
###begin p 75
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b083">83</xref>
###xml 939 941 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b084">84</xref>
###xml 1137 1145 1137 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g009">Figure 9</xref>
###xml 1147 1148 1147 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g009">9</xref>
###xml 5 17 <span type="species:ncbi:9606">participants</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
Male participants were examined using a portable ultrasound machine (SonoSite 180 Plus; SonoSite, Bothell, Washington, United States) equipped with a 7.5 MHZ linear transducer as described previously [83]. Briefly, patients were screened for worm nests in the scrotal area. Each detected worm nest was documented using print outs in b-, m-, and pulse-wave Doppler modes. Additionally, worms in lymphatic vessels were recorded on DVtapes using a SonyPC 120E Handycam (Sony, Tokyo, Japan) connected to the ultrasound machine in order to get an animated documentation of the moving worms. Dilation of the supratesticular lymphatic vessels containing no worm nests was determined by measuring the largest diameter using the two-dimensional b-mode. Since there is no grading system for lymphatic dilation, we developed a grading system to determine the degree of lymphatic dilation as follows: category 0 = no dilation (normally up to 0.10 cm [84], category 1 = the maximally dilated vessel has a dilation up to 0.20 cm, category 2 = dilation from 0.21-0.50 cm, category 3 = dilation from 0.51-1.0 cm, and category 4 = dilation above 1.0 cm (Figure 9A-9D). The procedure was repeated 12 and 24 mo after treatment.
###end p 75
###begin title 76
Determination of microfilarial load.
###end title 76
###begin p 77
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b044">44</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b044">44</xref>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 354 361 <span type="species:ncbi:9606">patient</span>
###xml 497 505 <span type="species:ncbi:9606">patients</span>
For a quick screening in the night, the microfilarial load was determined by microscopic examination of finger-prick blood samples as published [44]. Subsequently, eligible patients donated 10 ml of venous blood for accurate quantification using Whatman Nucleopore filter method as described previously [44]. The same volume of blood was taken from each patient 4 and 12 mo after the commencement of doxycycline treatment, but a lesser volume of 7 ml was taken at 24 mo due to complaints from the patients. At each time point, plasma was taken from the remaining sample, aliquoted, and frozen at -80 degreesC for later analysis of antigenemia and lymphangiogenic factors.
###end p 77
###begin title 78
###xml 17 26 17 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
Determination of Wolbachia levels in MF by PCR.
###end title 78
###begin p 79
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 57 79 57 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">W. bancrofti Wolbachia</italic>
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ftsZ</italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b044">44</xref>
###xml 611 633 611 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">W. bancrofti Wolbachia</italic>
###xml 634 638 634 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ftsZ</italic>
###xml 734 756 734 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">W. bancrofti Wolbachia</italic>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ftsZ</italic>
###xml 57 69 <span type="species:ncbi:6293">W. bancrofti</span>
###xml 611 623 <span type="species:ncbi:6293">W. bancrofti</span>
###xml 734 746 <span type="species:ncbi:6293">W. bancrofti</span>
Wolbachia content was quantified by real-time PCR of the W. bancrofti Wolbachia-ftsZ gene, derived from 500-1,000 microfilariae using a Rotor-Gene 3000 (Corbett Research, Brussels, Belgium) at pretreatment and 4, 12, and 24 mo after treatment. Details of the technique are given in reference [44]. Briefly, DNA was extracted with DNeasy kit (Qiagen, Hilden, Germany) following manufacturer's protocol with Proteinase K digestion. For the quantification, primers and a Taqman hybridization probe with the fluorescent dye 6-FAM (6-carboxyfluorescein) (Qiagen) were used to amplify a 286-base pair fragment of the W. bancrofti Wolbachia-ftsZ. The products were quantified by comparing with a standard curve of the plasmid containing the W. bancrofti Wolbachia-ftsZ fragment.
###end p 79
###begin title 80
Determination of circulating filarial antigenemia.
###end title 80
###begin p 81
###xml 86 98 86 98 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">W. bancrofti</named-content>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b042">42</xref>
###xml 86 98 <span type="species:ncbi:6293">W. bancrofti</span>
For determination of circulating filarial antigenemia (filarial adult worm antigens), W. bancrofti antigen was measured with the TropBio ELISA test kit (TropBio, Townsville, Australia). The manufacturer's protocol was followed except that the samples were diluted (1:20 ratio) with the diluent [42] before pipetting into the TropBio ELISA test plates. Samples were tested in duplicate before treatment and at 12- and 24-mo follow-ups. The optical density at 414 nm was recorded from plasma samples. Antigen units were calculated with a standard curve from standards provided by the manufacturer, and the final units multiplied by the dilution factor of 20.
###end p 81
###begin title 82
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Limb measurement of lymphedema patients.
###end title 82
###begin p 83
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b085">85</xref>
The circumference of both affected and normal legs were measured with measuring tape at five different points. Measurements were taken at 10 cm from the large toe, and 12 cm, 20 cm, 30 cm and 50 cm from the sole of the foot as described in reference [85], and the average of the five measurements taken as the mean circumference of the leg. Measurements were taken before and 12 mo post therapy.
###end p 83
###begin title 84
Grading or staging of lymphedema legs.
###end title 84
###begin p 85
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b047">47</xref>
###xml 111 120 111 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020092-g010">Figure 10</xref>
Grading or staging of lymphedema was performed along the guidelines of "Basic Lymphedema Management" [47] (see Figure 10.)
###end p 85
###begin p 86
###xml 332 339 <span type="species:ncbi:9606">patient</span>
Stage 1 = swelling that is reversible overnight, Stage 2 = swelling that is not reversible overnight, Stage 3 = shallow skin folds (ankle), Stage 4 = presence of knobs (lumps or protrusions), Stage 5 = deep skin folds plus knobs, Stage 6 = deep skin folds plus knobs and mossy lesions, and Stage 7 = parameters mentioned above plus patient is unable to perform routine daily activities.
###end p 86
###begin title 87
Foot care and ADL.
###end title 87
###begin p 88
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
Before the treatment began, all lymphedema patients were taught about hygienic care and physical exercises for the affected legs, and importantly, daily cleansing of affected legs with soap and water, and keeping the affected leg dry between washes. All the lymphedema patients were given soap, towels, and plastic bowls for washing the legs. They were visited every 6 mo in their villages. At each visit, the patients were asked through a questionnaire the number of attacks experienced.
###end p 88
###begin title 89
Serology test.
###end title 89
###begin p 90
###xml 191 200 191 200 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">B. malayi</named-content>
###xml 247 262 247 262 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Mastomys coucha</named-content>
###xml 826 835 811 820 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">B. malayi</named-content>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 191 200 <span type="species:ncbi:6279">B. malayi</span>
###xml 247 262 <span type="species:ncbi:35658">Mastomys coucha</span>
###xml 826 835 <span type="species:ncbi:6279">B. malayi</span>
###xml 1055 1060 <span type="species:ncbi:9606">human</span>
Filarial antibodies were measured from all the lymphedema patients before and 12 mo after treatment using the indirect immunofluorescence antibody (IIFA) test. For antigen preparation, adult B. malayi males were recovered 6 mo post infection from Mastomys coucha. Parasites were washed and stored at 4 degreesC for 4 h. They were then placed in canine musculature, frozen, and 7-mum sections were prepared and transferred onto glass slides. Quality was controlled by using a defined internal control serum (titer 1:320). For the IIFA test, 100 mul of plasma was inactivated at 56 degreesC for 30 min, and diluted 1:10 in PBS (pH 7.2). Seven-fold serial dilutions to 1:1,280 were made from the initial 1:10 screening dilution. A 10-mul volume of each of the diluted samples was added to separate wells on slides containing the B. malayi antigens, and incubated at 37 degreesC in a humid chamber for 45 min. After the incubation, the IIFA slides were washed four times for 20 min (3x in 0.1M PBS and 1x in deionized water). A fluorescein-labeled anti-total human immunoglobulin (Fluoline-H; bioMerieux, Marcy l'Etoile, France) diluted 1:90 in PBS was applied to each well and incubated for 45 min at 37 degreesC in a humid chamber. The slides were washed four times for 20 min (3x in 0.1M PBS and 1x in deionized water). Excess water was removed and the slides dried, covered with glycerol (Euroimmun, Luebeck, Germany), and cover slides. Wells were observed with a immunofluorescence microscope (Ernst Leitz, Wetzlar, Germany). Fluorescence of either the complete worm section including mesenchym and cuticle or only mesenchym was defined as positive. Fluorescence of the mesenchym without cuticle was regarded as non-specific. A titer of nore than 1:80 (including cuticle fluorescence) was regarded as indicative for filarial infection. A titer equal to or less than 1:20 was regarded as negative. Positive and negative controls were included in the test. This test is validated in regular intervals within a German network of laboratories for quality control.
###end p 90
###begin title 91
Determination of plasma levels of VEGF-C and sVEGFR-3.
###end title 91
###begin p 92
###xml 7 15 <span type="species:ncbi:9606">patients</span>
In all patients, the plasma concentrations of VEGF-C and sVEGFR-3 were measured using Quantikine immunoassay ELISA kits according to the manufacturer's instructions (R&D Systems). After stopping the reaction, plates were read at 450 nm and 540 nm with a microplate reader (SPECTRAmax 340PC; Sunnyvale, California, United States). Twenty-three endemic normals, i.e., residents of the same endemic area with no evidence of infection confirmed by the lack of mircofilaraemia and lack of circulating Og4C3 filarial antigen, despite exposure to infective larvae borne by mosquitoes, were included as controls.
###end p 92
###begin title 93
Data analysis.
###end title 93
###begin p 94
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 1144 1145 1142 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1353 1354 1351 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1370 1371 1368 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 776 784 <span type="species:ncbi:9606">patients</span>
Wolbachia loads in worm tissue and microfilaremia were summarized as geometric means (GM). Differences in GM at baseline and subsequent follow-ups were analyzed using the Wilcoxon signed rank and Mann-Whitney U tests. Changes in the degree of antigenemia were calculated as percentages from baseline and analyzed between treatment groups at subsequent follow-up time points by the Mann-Whitney U test. Proportions of MF-positive and MF-negative individuals as well as individuals showing the fFDS before and after treatment were compared using Fisher' exact tests. Plasma levels of the VEGF molecules were expressed as mean +/- standard deviations (SD), and differences in the levels of the VEGF molecules between endemic normals, microfilaremic (MF-positive), and lymphedema patients were analyzed using analysis of variance (ANOVA) with the Bonferroni/Dunn post hoc test. Differences in the levels of the VEGFs within the treatment groups before and 12 mo after treatment as well as changes in lymphatic vessel dilation, stages of lymphedema, and the size of affected limbs of lymphedema before and after treatment were assessed using paired t-tests. Positive relationships between the disease states and the VEGF molecules were assessed by the Spearman' rank correlation test and simple regression analysis (coefficient of determination indicated as r). A two-tailed p-value lower than 0.05 was considered significant. Independence of data was tested using multivariate analysis. All analyses were done using StatView version X for Mac OS 9.5.
###end p 94
###begin title 95
Supporting Information
###end title 95
###begin title 96
Accession Numbers
###end title 96
###begin p 97
###xml 145 175 145 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wuchereria bancrofti Wolbachia</italic>
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ftsZ</italic>
###xml 145 165 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
The GenBank () accession numbers for the gene and gene products discussed in this paper are: soluble VEGFR-3 (NM_002020); VEGF-C (CAA63907); and Wuchereria bancrofti Wolbachia-ftsZ gene (AF081198).
###end p 97
###begin p 98
We thank the individuals of the District Health Management team at Axim (Nzema East District), Western Region, Ghana, for their cooperation.
###end p 98
###begin title 99
Abbreviations
###end title 99
###begin p 100
adenolymphangitis
###end p 100
###begin p 101
circulating filarial antigen
###end p 101
###begin p 102
diethylcarbamazine
###end p 102
###begin p 103
enzyme-linked immunosorbent assay
###end p 103
###begin p 104
filarial dance sign
###end p 104
###begin p 105
geometric means
###end p 105
###begin p 106
interleukin
###end p 106
###begin p 107
lymphatic filariasis
###end p 107
###begin p 108
microfilaria
###end p 108
###begin p 109
standard deviations
###end p 109
###begin p 110
soluble vascular endothelial growth factor receptor-3
###end p 110
###begin p 111
tumor necrosis factor
###end p 111
###begin p 112
ultrasonography
###end p 112
###begin p 113
vascular endothelial growth factor
###end p 113
###begin p 114
vascular endothelial growth factor receptor-3
###end p 114
###begin title 115
References
###end title 115
###begin article-title 116
Elimination of lymphatic filariasis as a public health problem
###end article-title 116
###begin article-title 117
###xml 58 78 58 78 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 58 78 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo
###end article-title 117
###begin article-title 118
Mass treatment to eliminate filariasis in Papua New Guinea
###end article-title 118
###begin article-title 119
Long-term effect of three different strategies for mass diethylcarbamazine administration in bancroftian filariasis: Follow-up at 10 years after treatment
###end article-title 119
###begin article-title 120
Mass DEC chemotherapy for control of bancroftian filariasis: Comparative efficacy of four strategies two years after start of treatment
###end article-title 120
###begin article-title 121
A randomized, double-blind, placebo-controlled study with diethylcarbamazine for the treatment of hydrocoele in an area of Tanzania endemic for lymphatic filariasis
###end article-title 121
###begin article-title 122
The efficacies of affected-limb care with penicillin diethylcarbamazine, the combination of both drugs or antibiotic ointment, in the prevention of acute adenolymphangitis during bancroftian filariasis
###end article-title 122
###begin article-title 123
###xml 100 105 <span type="species:ncbi:9606">human</span>
Lymphoscintigraphic assessment of the effect of diethylcarbamazine treatment on lymphatic damage in human bancroftian filariasis
###end article-title 123
###begin article-title 124
A randomized clinical trial to compare the efficacy of three treatment regimens along with footcare in the morbidity management of filarial lymphedema
###end article-title 124
###begin article-title 125
Chemotherapy for lymphatic filariasis: Progress but not perfection
###end article-title 125
###begin article-title 126
###xml 85 103 85 103 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Rutaceae aurantiae</named-content>
Some observations on the effect of Daflon (micronized purified flavonoid fraction of Rutaceae aurantiae) in bancroftian filarial lymphedema
###end article-title 126
###begin article-title 127
LF disease-Clinical management. In: Towards a strategic plan for research to support the global program to eliminate lymphatic filariasis. Summary of immediate needs and opportunities for research on lymphatic filariasis. Philadelphia, Pennsylvania, USA, December 9-10, 2003
###end article-title 127
###begin article-title 128
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
Wolbachia bacteria of filarial nematodes
###end article-title 128
###begin article-title 129
###xml 26 35 26 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness
###end article-title 129
###begin article-title 130
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 46 51 <span type="species:ncbi:9606">human</span>
Wolbachia in the inflammatory pathogenesis of human filariasis
###end article-title 130
###begin article-title 131
###xml 22 41 22 41 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Onchocerca volvulus</named-content>
###xml 111 120 111 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 22 41 <span type="species:ncbi:6282">Onchocerca volvulus</span>
Immunopathogenesis of Onchocerca volvulus keratitis (river blindness): A novel role for TLR4 and endosymbiotic Wolbachia bacteria
###end article-title 131
###begin article-title 132
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Renal abnormalities in microfilaremic patients with Bancroftian filariasis
###end article-title 132
###begin article-title 133
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Clinical, parasitologic, and immunologic observations of patients with hydrocele and elephantiasis in an area with endemic lymphatic filariasis
###end article-title 133
###begin article-title 134
Pathogenesis of lymphatic disease in bancroftian filariasis: A clinical perspective
###end article-title 134
###begin article-title 135
###xml 34 39 <span type="species:ncbi:9606">human</span>
Aping Jane Goodall: Insights into human lymphatic filariasis
###end article-title 135
###begin article-title 136
Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation
###end article-title 136
###begin article-title 137
Molecular mechanisms of lymphangiogenesis
###end article-title 137
###begin article-title 138
Lymphangiogenesis and lymphangiodysplasia: From molecular to clinical lymphology
###end article-title 138
###begin article-title 139
Lymphedema: An immunologically vulnerable site for development of neoplasms
###end article-title 139
###begin article-title 140
Insights into the molecular pathogenesis and targeted treatment of lymphedema
###end article-title 140
###begin article-title 141
Signaling angiogenesis and lymphangiogenesis
###end article-title 141
###begin article-title 142
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
###end article-title 142
###begin article-title 143
###xml 100 115 <span type="species:ncbi:10090">transgenic mice</span>
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice
###end article-title 143
###begin article-title 144
Vascular endothelial growth factor C induces angiogenesis in vivo
###end article-title 144
###begin article-title 145
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
###xml 102 105 <span type="species:ncbi:9606">man</span>
The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man
###end article-title 145
###begin article-title 146
###xml 43 58 <span type="species:ncbi:10090">transgenic mice</span>
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
###end article-title 146
###begin article-title 147
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
###end article-title 147
###begin article-title 148
VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
###end article-title 148
###begin article-title 149
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
Wolbachia bacteria in filarial immunity and disease
###end article-title 149
###begin article-title 150
###xml 61 76 <span type="species:ncbi:10090">transgenic mice</span>
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3
###end article-title 150
###begin article-title 151
Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C
###end article-title 151
###begin article-title 152
###xml 56 69 56 69 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Brugia malayi</named-content>
###xml 138 147 138 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 56 69 <span type="species:ncbi:6279">Brugia malayi</span>
Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria
###end article-title 152
###begin article-title 153
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Proinflammatory cytokines secreted by monocytes of filarial patients
###end article-title 153
###begin article-title 154
###xml 47 56 47 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 85 104 85 104 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Onchocerca volvulus</named-content>
###xml 85 104 <span type="species:ncbi:6282">Onchocerca volvulus</span>
###xml 196 201 <span type="species:ncbi:9606">human</span>
Lipopolysaccharide-like molecules derived from Wolbachia endobacteria of the filaria Onchocerca volvulus are candidate mediators in the sequence of inflammatory and anti-inflammatory responses of human monocytes
###end article-title 154
###begin article-title 155
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
Wolbachia bacterial endosymbionts of filarial nematodes
###end article-title 155
###begin article-title 156
###xml 57 77 57 77 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 57 77 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: A double-blind, randomised placebo-controlled trial
###end article-title 156
###begin article-title 157
Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis
###end article-title 157
###begin article-title 158
###xml 76 85 76 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 105 125 105 125 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 105 125 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
Doxycycline as a novel strategy against bancroftian filariasis-Depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilariae production
###end article-title 158
###begin article-title 159
###xml 129 149 129 149 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 129 149 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection
###end article-title 159
###begin article-title 160
###xml 41 61 41 61 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 41 61 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
###xml 74 79 <span type="species:ncbi:9606">women</span>
Reliable and frequent detection of adult Wuchereria bancrofti in Ghanaian women by ultrasonography
###end article-title 160
###begin article-title 161
Essential tools-Drugs and clinical drug trials. In: Towards a strategic plan for research to support the global program to eliminate lymphatic filariasis. Summary of immediate needs and opportunities for research on lymphatic filariasis. Philadelphia, Pennsylvania, USA, December 9-10, 2003
###end article-title 161
###begin article-title 162
Mass drug treatment for lymphatic filariasis and onchocerciasis
###end article-title 162
###begin article-title 163
Final report of the Conference on the Eradicability of Onchocerciasis
###end article-title 163
###begin article-title 164
###xml 66 75 66 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 144 154 144 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Onchocerca</italic>
###xml 32 37 <span type="species:ncbi:9606">human</span>
Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms
###end article-title 164
###begin article-title 165
###xml 13 22 13 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wolbachia</italic>
###xml 39 58 39 58 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Onchocerca volvulus</named-content>
###xml 39 58 <span type="species:ncbi:6282">Onchocerca volvulus</span>
Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment
###end article-title 165
###begin article-title 166
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin
###end article-title 166
###begin article-title 167
Essential tools-Diagnostics. In: Towards a strategic plan for research to support the global program to eliminate lymphatic filariasis. Summary of immediate needs and opportunities for research on lymphatic filariasis. Philadelphia, Pennsylvania, USA, December 9-10, 2003
###end article-title 167
###begin article-title 168
A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana
###end article-title 168
###begin article-title 169
###xml 81 101 81 101 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 81 101 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
###xml 130 138 <span type="species:ncbi:9606">children</span>
The effect of single dose ivermectin alone or in combination with albendazole on Wuchereria bancrofti infection in primary school children in Tanzania
###end article-title 169
###begin article-title 170
Albendazole for the control and elimination of lymphatic filariasis: systematic review
###end article-title 170
###begin article-title 171
###xml 73 93 73 93 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 73 93 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
Evaluation of a monoclonal-antibody based antigen assay for diagnosis of Wuchereria bancrofti infection in Egypt
###end article-title 171
###begin article-title 172
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
###end article-title 172
###begin article-title 173
Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4
###end article-title 173
###begin article-title 174
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
###end article-title 174
###begin article-title 175
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3
###end article-title 175
###begin article-title 176
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
###end article-title 176
###begin article-title 177
Angiogenesis in breast cancer: how should we measure this? (Review)
###end article-title 177
###begin article-title 178
Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy
###end article-title 178
###begin article-title 179
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma
###end article-title 179
###begin article-title 180
###xml 61 81 61 81 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 61 81 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
Fine structure of intrascrotal lymphatic vessels infected by Wuchereria bancrofti adult worms
###end article-title 180
###begin article-title 181
###xml 27 47 27 47 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 27 47 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
###xml 71 74 <span type="species:ncbi:9606">men</span>
Occurrence of living adult Wuchereria bancrofti in the scrotal area of men with microfilaremia
###end article-title 181
###begin article-title 182
Prevention of acute adenolymphangitis in brugian filariasis: Comparison of the efficacy of ivermectin and diethylcarbamazine, each combined with local treatment of the affected limb
###end article-title 182
###begin article-title 183
A double-blind, placebo-controlled study of the efficacy of oral penicillin, diethylcarbamazine or local treatment of the affected limb in preventing acute adenolymphangitis in lymphedema caused by brugian filariasis
###end article-title 183
###begin article-title 184
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Episodic adenolymphagitis and lymphedema in patients with bancroftian filariasis
###end article-title 184
###begin article-title 185
The economic burden of lymphatic filariasis in northern Ghana
###end article-title 185
###begin article-title 186
The impact of lymphatic filariasis on labour inputs in southern India: Results of a multi-site study
###end article-title 186
###begin article-title 187
Filarial infections
###end article-title 187
###begin article-title 188
"Filarial" adenolymphangitis without filarial infection
###end article-title 188
###begin article-title 189
Reduction of filaritic lymphedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and the effects of diethylcarbamazine (DEC)
###end article-title 189
###begin article-title 190
Coumarin (Lodema)
###end article-title 190
###begin article-title 191
###xml 51 56 <span type="species:ncbi:9606">human</span>
Quantitative assessment of circulating antigens in human lymphatic filariasis: A field evaluation of monoclonal antibody-based ELISA using blood collected on filter strips
###end article-title 191
###begin article-title 192
###xml 31 44 31 44 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Brugia malayi</named-content>
###xml 21 25 <span type="species:ncbi:9685">cats</span>
###xml 31 44 <span type="species:ncbi:6279">Brugia malayi</span>
Chronic infection of cats with Brugia malayi and streptococcus
###end article-title 192
###begin article-title 193
Skin changes in filarial and non-filarial lymphedema of the lower extremities
###end article-title 193
###begin article-title 194
###xml 87 107 87 107 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Wuchereria bancrofti</named-content>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 87 107 <span type="species:ncbi:6293">Wuchereria bancrofti</span>
Soluble cellular adhesion molecules, selectins, VEGF and endothelin-1 in patients with Wuchereria bancrofti infection and association with clinical status
###end article-title 194
###begin article-title 195
Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase
###end article-title 195
###begin article-title 196
Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis
###end article-title 196
###begin article-title 197
###xml 59 64 <span type="species:ncbi:9606">human</span>
Arrangement and fine structure of lymphatic vessels in the human spermatic cord
###end article-title 197
###begin article-title 198
The clinical manifestations of lymphatic filariasis
###end article-title 198
###begin title 199
Figures and Tables
###end title 199
###begin title 200
###xml 13 20 <span type="species:ncbi:9606">Patient</span>
Flowchart of Patient Participation
###end title 200
###begin p 201
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
(A) Trial profile of microfilaremic patients. Of the 76 patients, 33 (17 doxycycline and 16 placebo) patients were present at all time points.
###end p 201
###begin p 202
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
(B) Trial profile of lymphedema patients. Of the 19 patients, 18 (eight doxycycline and ten placebo) patients were present at all time points.
###end p 202
###begin title 203
The Effect of Doxycycline Treatment on the Supratesticular Lymphatic Vessel Dilation at Various Time Points
###end title 203
###begin p 204
###xml 284 285 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 291 292 289 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 347 348 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 362 363 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
The supratesticular lymphatic vessel dilation (mean of category +/- SD) was determined before treatment, and 12 and 24 mo thereafter, using USG. The mean supratesticular lymphatic vessel dilation of doxycycline-treated (Doxy) patients improved significantly compared to pretreatment (n = 9, p = 0.0404) at 24 mo, in contrast to the placebo group (n = 8) (paired t-test).
###end p 204
###begin title 205
###xml 58 66 <span type="species:ncbi:9606">Patients</span>
Pretreatment Plasma Levels of VEGF-C in Filarial-Infected Patients and Endemic Controls
###end title 205
###begin p 206
###xml 121 122 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 155 156 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 186 187 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 312 313 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 349 350 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 399 400 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 512 513 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
Plasma concentrations (mean +/- SD) of VEGF-C were measured, using a commercial kit, from plasma of lymphedema patients (n = 26), microfilaremic patients (n = 76), and endemic controls (n = 23, who did not have filarial infection). Mean plasma levels of VEGF-C were significantly elevated in the microfilaremic (p < 0.0001) and lymphedema patients (p = 0.0002) compared to endemic controls (Student t-test with Bonferroni/Dunn correction). There was no difference between microfilaremic and lymphedema patients (p = 0.8033).
###end p 206
###begin title 207
###xml 59 67 <span type="species:ncbi:9606">Patients</span>
Pretreatment Plasma Levels of sVEGFR-3 in Filaria-Infected Patients and Endemic Controls
###end title 207
###begin p 208
###xml 121 122 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 155 156 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 186 187 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 314 315 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 351 352 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 401 402 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 507 508 505 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
###xml 497 505 <span type="species:ncbi:9606">patients</span>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
Plasma concentrations (mean +/- SD) of sVEGFR-3 were measured using a commercial kit from plasma of lymphedema patients (n = 26), microfilaremic patients (n = 76), and endemic controls (n = 23, who did not have filarial infection). Mean plasma levels of sVEGFR-3 were significantly elevated in the microfilaremic (p = 0.0006) and lymphedema patients (p = 0.0012) compared to endemic controls (Student t-test with Bonferroni/Dunn correction). sVEGFR-3 was also significantly elevated in lymphedema patients (p = 0.0024) compared to microfilaremic patients.
###end p 208
###begin title 209
###xml 42 50 <span type="species:ncbi:9606">Patients</span>
Plasma Levels of VEGF-C of Microfilaremic Patients before and 12 Mo after Doxycycline Treatment
###end title 209
###begin p 210
###xml 185 192 183 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t001">Table 1</xref>
###xml 297 304 295 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t002">Table 2</xref>
###xml 343 344 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 412 413 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
Plasma concentrations (mean +/- SD) of VEGF-C were measured from plasma of microfilaremic patients before and 12 mo after doxycycline treatment (17 doxycycline treated, 16 placebo, see Table 1). The VEGF-C levels decreased significantly at 12 mo (preceding supratesticular lymphatic dilation, see Table 2) in the doxycycline-treated patients (p = 0.0198), but no difference in the placebo group occurred (paired t-test).
###end p 210
###begin title 211
###xml 44 52 <span type="species:ncbi:9606">Patients</span>
Plasma Levels of sVEGFR-3 of Microfilaremic Patients before and 12 Mo after Doxycycline Treatment
###end title 211
###begin p 212
###xml 187 194 185 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t001">Table 1</xref>
###xml 301 308 299 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0020092-t002">Table 2</xref>
###xml 347 348 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 465 466 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
Plasma concentrations (mean +/- SD) of sVEGFR-3 were measured from plasma of microfilaremic patients before and 12 mo after doxycycline treatment (17 doxycycline treated, 16 placebo, see Table 1). The sVEGFR-3 levels decreased significantly at 12 mo (preceding supratesticular lymphatic dilation, see Table 2) in the doxycycline-treated patients (p = 0.0125) to a level close to that of endemic controls whereas there was no difference in the placebo group (paired t-test).
###end p 212
###begin title 213
###xml 38 46 <span type="species:ncbi:9606">Patients</span>
Plasma Levels of VEGF-C of Lymphedema Patients before and 12 Mo after Doxycycline Treatment
###end title 213
###begin p 214
###xml 229 230 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 283 284 281 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
Plasma concentrations (mean +/- SD) of VEGF-C were measured from plasma of lymphedema patients before and 12 mo after doxycycline treatment. The VEGF-C levels decreased significantly at 12 mo in the doxycycline-treated patients (p = 0.0499), in contrast to the placebo group (paired t-test).
###end p 214
###begin title 215
###xml 40 48 <span type="species:ncbi:9606">Patients</span>
Plasma Levels of sVEGFR-3 of Lymphedema Patients before and 12 Mo after Doxycycline Treatment
###end title 215
###begin p 216
###xml 233 234 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 306 307 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
Plasma concentrations (mean +/- SD) of sVEGFR-3 were measured from plasma of lymphedema patients before and 12 mo after doxycycline treatment. The sVEGFR-3 levels decreased significantly at 12 mo in the doxycycline-treated patients (p = 0.0251) whereas there was no difference in the placebo group (paired t-test).
###end p 216
###begin title 217
###xml 78 86 <span type="species:ncbi:9606">Patients</span>
Grading of the Supratesticular Lymphatic Vessel Dilation of Filarial-Infected Patients Displayed by USG
###end title 217
###begin p 218
###xml 279 287 <span type="species:ncbi:9606">patients</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
###xml 486 494 <span type="species:ncbi:9606">patients</span>
Dilation of the supratesticular lymphatic vessels was determined by measuring the largest diameter detectable in the two-dimensional b-mode of a portable ultrasound machine. A grading system was developed to determine the degree of lymphatic dilation as follows: (A) category 1: patients with minimal lymphatic dilation of up to 0.2 cm; (B) category 2: patients with mild dilation from 0.21-0.50 cm; (C) category 3: patients with moderate dilation from 0.51-1.0 cm; and (D) category 4: patients with severe dilation of above 1.0 cm.
###end p 218
###begin title 219
Lymphedema Stages
###end title 219
###begin p 220
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020092-b047">47</xref>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
The lymphedema stages according to the classification by Dreyer et al. [47]; patients are from this study.
###end p 220
###begin p 221
(A) Stage 2, swelling that is not reversible overnight.
###end p 221
###begin p 222
(B) Stage 3, shallow skin folds at the ankle.
###end p 222
###begin p 223
(C) Stage 4, alteration of skin texture and formation of knobs (arrowheads).
###end p 223
###begin p 224
(D) Stage 5, presentation of deep skin folds in addition to the alterations of stage 4;
###end p 224
###begin p 225
(E) Satge 6, presentation of mossy lesion in addition to the alterations of stage 5.
###end p 225
###begin p 226
###xml 26 33 <span type="species:ncbi:9606">patient</span>
(F) Stage 7, inability of patient to perform daily work.
###end p 226
###begin p 227
###xml 72 80 <span type="species:ncbi:9606">Patients</span>
Primary Variables Measured before and after Treatment in Microfilaremic Patients
###end p 227
###begin p 228
###xml 38 46 <span type="species:ncbi:9606">Patients</span>
State of Lymphatic Vessel Dilation of Patients before and 24 Months after Doxycycline Treatment
###end p 228
###begin p 229
###xml 68 76 <span type="species:ncbi:9606">Patients</span>
Primary Variables Measured before and after Treatment in Lymphedema Patients
###end p 229
###begin p 230
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 230
###begin p 231
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. AH, MT, and OA conceived and designed the experiments. AYD, SM, SS, YMD, LB, KP, and JL performed the experiments. AYD, SM, BL, and AH analyzed the data. AYD, SM, and AH wrote the paper.
###end p 231
###begin p 232
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. We are grateful for financial support from the European Commission (EU grant ICA4-CT-2002-10051) and the VW-Foundation (grant I/7352). Pfizer Inc, Karlsruhe, Germany, generously provided Vibramycin and placebo tablets. AYD is a recipient of scholarship from the German Academic Exchange Service (DAAD) for his PhD work.
###end p 232

